Adicet bio announces positive interim clinical data from first-ever allogeneic, off-the-shelf, gamma delta car t investigational cell therapy

Menlo park, calif. and boston, dec. 06, 2021 (globe newswire) -- adicet bio, inc. (nasdaq: acet), a biotechnology company discovering and developing first-in-class allogeneic gamma delta car t cell therapies for cancer and other diseases, today announced positive interim data from its dose escalation phase 1 study evaluating the safety and tolerability of adi-001, adicet's investigational therapy targeting cd20 for the potential treatment of b-cell non-hodgkin's lymphoma.
ACET Ratings Summary
ACET Quant Ranking